Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vietnam Eyes Canada Handling Of Bayer Contraceptives Linked To Deaths

This article was originally published in PharmAsia News

Executive Summary

The Drug Administration of Vietnam said it is keeping a close watch on Canada's handling of reports of several deaths attributed to Bayer Healthcare's Yaz (drospirenone) and Yasmin, which adds ethinyl, both for birth control.

The Drug Administration of Vietnam said it is keeping a close watch on Canada's handling of reports of several deaths attributed to Bayer Healthcare's Yaz (drospirenone) and Yasmin, which adds ethinyl, both for birth control. The drugs have been approved for Vietnam's market, Yaz since 2010, nearly a year ago with the added label requirement to explain increased risks of blood clots. Health Canada linked nine deaths related to Yaz, 18 to Yasmin since they were approved in 1965, but offered none of the details the DAV wants to see. (Click here for more)

"Vietnam Health Authorities Wary Of Fatal Birth Control Pills" - Thanhnien (Thailand) (6/16/2013)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC084631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel